4//SEC Filing
Morrison Briggs 4
Accession 0001562180-23-006262
CIK 0001395937other
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 6:50 AM ET
Size
8.9 KB
Accession
0001562180-23-006262
Insider Transaction Report
Form 4
Morrison Briggs
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2023-08-09$8.77/sh+52,855$463,538→ 70,691 total - Sale
Common Stock
2023-08-09$18.27/sh−52,855$965,402→ 17,836 total - Exercise/Conversion
Stock Options (Right to buy)
2023-08-09−52,855→ 0 totalExercise: $8.77From: 2027-02-06→ Common Stock (52,855 underlying)
Footnotes (3)
- [F1]Following the sales reported in this Form 4, the Reporting Person has a total of 559,142 options to purchase shares of common stock that are vested and immediately exercisable and a total of 247,875 options to purchase shares of common stock that have not yet vested.
- [F2]The sale prices ranged from $18.02 to $18.41.
- [F3]This option is fully vested.
Documents
Issuer
Syndax Pharmaceuticals Inc
CIK 0001395937
Entity typeother
Related Parties
1- filerCIK 0001654430
Filing Metadata
- Form type
- 4
- Filed
- Aug 9, 8:00 PM ET
- Accepted
- Aug 10, 6:50 AM ET
- Size
- 8.9 KB